CJC-1295

Overview

CJC-1295 is a synthetic analog of GHRH that stimulates the pituitary to release growth hormone (GH). The 'with DAC' (Drug Affinity Complex) version has a markedly extended half-life (on the order of days vs. minutes/hours), producing a sustained rise in GH and IGF-1. A published human study (Walker et al., 2006, Journal of Clinical Endocrinology & Metabolism) showed CJC-1295 with DAC produced dose-dependent increases in plasma GH and IGF-1 lasting several days, with mean IGF-1 rising roughly 1.5- to 3-fold above baseline in healthy adults. It is commonly paired with ipamorelin. Despite pharmacologic data, it is not FDA-approved for human use and is prohibited in sport.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Increasing GH/IGF-1 for body composition (fat loss, lean-mass support) — marketed claim
• Recovery and sleep quality — marketed claim, limited controlled human outcome data
• Anti-aging / 'GH optimization' — marketed claim, not established

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Labs — IGF-1 (primary readout of GH-axis stimulation) at baseline and follow-up; fasting glucose and HbA1c (GH stimulation can affect insulin sensitivity)
• Body composition — InBody body-fat % and lean mass over time
• Whoop — slow-wave sleep (SWS) trend (GH secretion is sleep-linked) and recovery
• Subjective — sleep quality, recovery, water retention/joint discomfort

Sources & References

1. [1]Walker et al. 2006 — CJC-1295 sustained GH/IGF-1 increase in healthy adults (JCEM)
2. [2]CJC-1295 use in sports and military rules explained — BSCG
3. [3]WADA Prohibited List — official (GHRH analogues, GHS)